Latest Stock Buy or Sell?
Make More Informed Decisions!

Today, Robert McWhirter commented about whether NPI-T, EMP.A-T, DPM-T, GRN-T, SMF-T, VMD-T, CVX-X, PLC-T, SVA-X, NTR-T, BDGI-T, ATE-T, ARE-T, ALY-X, GSI-X, GSI-X, UGE-X, XBC-T, NVA-T, PNG-X are stocks to buy or sell.

COMMENT
The future of gold: he's been keen on gold for two months. Gold has broken $1,750 and on track to have its highest quarterly rise. He sees further upside in gold as well as copper. Often, both are mined and found at the same time. Teranga and Centerra will be huge cash flow generators in 2021. The small-cap gold stocks will also do well but are more leveraged than the large-caps who should do better. (Check his top picks today.) The long-term bull market is intact, but he feels we're now in a 5-7% pullback in the next 4-6 weeks, because North American stocks are overbought. But gold will continue to be strong. Long-term, the bull market still has 18 months to go.
Unknown
BUY
It's doing better now. Their sonor device looks for underwater mines and does underground mapping of pipelines. Earnings are expected to leap to 5 cents in 2021 to give it a 10x PE. If so, then there's a $1 target minimum. Lots of upside.
Technology
DON'T BUY
Nuvista Energy Ltd
It took a big haircut in earnings in the last 90 days, down 57% this year and a projected 20% in 2021. Cash flow will shrink this year but expected to grown next year, but still lags its peers. NVA is a reasonable speculation, but he sees a better play in natural gas names in the next 12 months, considered The Energy Trade of the Decade.
oil / gas
STRONG BUY
Xebec Adsorption

He's owned this for a long time.They're a master of renewable energy, particularly natural gas, in North America and Europe. Their hydrogen business will leap--hydrogen and clean energy are huge now (look at Ballard Power's performance). 2021's earnings are expected to grow 35%. $5.15 is the target price.

INDUSTRIAL PRODUCTS
BUY

UGE boasts a US$72 million backlog, a huge increase in less than three months. That backlog is 40x last quarter's annualized sales run rate. Their enterprise value is 10% of their backlog. They focus on New York state and the Philippines. UGE is transitioning their business model to resemble Xebec's to raise recurring revenues and margins. His price target is 50-70 cents and will likely rise as earnings come in and impress markets.

0
BUY
They make video systems for school and transit buses, as well as trains. Clients include the Philadelphia transit system. Their systems protect children and transit passengers from illegally passing cars. GSI is just getting started, but positive Philly results should encourage sales elsewhere like New York.
Technology
BUY
They make video systems for school and transit buses, as well as trains. Clients include the Philadelphia transit system. Their systems protect children and transit passengers from illegally passing cars. GSI is just getting started, but positive Philly results should encourage sales elsewhere like New York.
Technology
BUY
Analytixinsight

It's like they're building the discount brokerage arm for Royal Bank--they have a partnership with a huge Italian bank, Sanpaolo, and are thoroughly testing that system--testing is almost complete and they're awaiting government approval. Once the Italian government approves them by end-September, the new discount brokerage system could lead to a spin-out by the end of the year. This is a great long-term opportunity. ALY can build other systems at other European banks.

0
PAST TOP PICK
Aecon Group Inc
(A Top Pick Aug 01/19, Down 25%) People are concerned about construction levels, but ARE will do okay. He stopped out.
contractors
PAST TOP PICK
(A Top Pick Aug 01/19, Up 24%) There's been a lot going here: the reported good phase 2 drug test results. They did financing recently and are planning for phase 3 which will cost $50 million, so they have enough cash for 18 months. The next phase will start in Q2 2021 and last two years. Generally, drugs that pass phase 2 have a good outlook entering phase 3. ATE continues to talk to third parties about mass-producing the drug.
Pharma & Healthcare
PAST TOP PICK
Badger Daylighting
(A Top Pick Aug 01/19, Down 40%) BAD is associated with shale oil, which of course hasn't done well. But BAD has a mobile fleet that can perform other work. There are better stocks elsewhere, including gold.
oil / gas
DON'T BUY
Nutrien Ltd.
Earnings have been chopped 16% for 2020 and 7% for 2021. Pays a 5.2% dividend and has a slight positive free cash flow, which should grow 2% this year and 2% next. It trades at 9.8x enterprise value to cash flow, which he ranks as a B-. The yield is nice, but NTR has weak earnings growth.
agriculture
BUY
Sernova Corp.
They make a tiny device that you implant into your chest to create insulin. The medical benefits are high and could have additional applications. Tests are exploring how the device can deliver other drugs into the body, and early results are promising. He sees a lot of upside.
biotechnology
DON'T BUY
Park Lawn Corp
Pays a 2% dividend yield with 4% free cash flow. Earnings to grow 5% this year, and 32% in 2021. Currently, the stock isn't doing much. You can hang onto it for a year, but don't buy.
other services
BUY
He owns a lot of this. Earnings are expected to be 4 cents next year. They boast a big $50 million sales backlog, spiking up from last year. The business is quite sound--they remove stones and sand out of cement, so this will benefit from announced infrastructure spending. Upside to come.
INDUSTRIAL PRODUCTS